Status: This is the original version (as it was originally adopted).

## ANNEX

In point A of Annex III to Directive 2004/37/EC, the following rows are added:

Name of agent	EC No ( <sup>1</sup> )	CAS No ( <sup>2</sup> )	Limit values						NotationTransitional	
			()			Short-term ( <sup>4</sup> )				measures
			mg/ m <sup>3</sup> ( <sup>5</sup> )	ppm ( <sup>6</sup>	) f/ ml ( <sup>7</sup> )	mg/ m <sup>3</sup> ( <sup>5</sup> )	ppm ( <sup>6</sup>	) f/ ml ( <sup>7</sup> )		
'Cadmir and its inorgan compou	ic		0,001 <sup>a</sup>							Limit value 0,004 mg/ m <sup>3b</sup> until 11 July 2027
Berylliu and inorgan berylliu compou	ic m		0,0002ª						dermal and respirate sensitisa	value by0006
Arsenic acid and its salts, as well as inorgan arsenic compou	ic		0,01ª							For the copper smelting sector, the limit value shall apply from 11 July 2023
Formalo	1 <b>210/040</b> 01	I- <del>3</del> 0-00-0	0,37	0,3		0,74	0,6		dermal sensitisa	


a Inhalable fraction.

**b** Inhalable fraction. Respirable fraction in those Member States that implement, on the date of the entry into force of this Directive, a biomonitoring system with a biological limit value not exceeding 0,002 mg Cd/g creatinine in urine.

**c** The substance can cause sensitisation of the skin and of the respiratory tract.

d The substance can cause sensitisation of the skin.'.

Status: This is the original version (as it was originally adopted).



c The substance can cause sensitisation of the skin and of the respiratory tract.

**d** The substance can cause sensitisation of the skin.'.